The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
Open accessAbstract
BACKGROUND: In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial. METHODS: HIV-infected infants 6 to 12 weeks of age with a CD4 lymphocyte percentage (the CD4 percentage) of 25% or more were randomly assigned to receive antiretroviral therapy (lopinavir-ritonavir, zidovudine, and lamivudine) when the CD4 percentage decreased to less than 20% (or 25% if the child was younger than 1 year) or clinical criteria were met (the deferred antiretroviral-therapy group) or to immediate initiation of limited antiretroviral therapy until 1 year of age or 2 years of age (the early antiretroviral-therapy groups). We report the early outcomes for infants who received deferred antiretroviral therapy as compared with early antiretroviral therapy. RESULTS: At a median age of 7.4 weeks (interquartile range, 6.6 to 8.9) and a CD4 percentage of 35.2% (interquartile range, 29.1 to 41.2), 125 infants were randomly assigned to receive deferred therapy, and 252 infants were randomly assigned to receive early therapy. After a median follow-up of 40 weeks (interquartile range, 24 to 58), antiretroviral therapy was initiated in 66% of infants in the deferred-therapy group. Twenty infants in the deferred-therapy group (16%) died versus 10 infants in the early-therapy groups (4%) (hazard ratio for death, 0.24; 95% confidence interval [CI], 0.11 to 0.51; P<0.001). In 32 infants in the deferred-therapy group (26%) versus 16 infants in the early-therapy groups (6%), disease progressed to Centers for Disease Control and Prevention stage C or severe stage B (hazard ratio for disease progression, 0.25; 95% CI, 0.15 to 0.41; P<0.001). Stavudine was substituted for zidovudine in four infants in the early-therapy groups because of neutropenia in three infants and anemia in one infant; no drugs were permanently discontinued. After a review by the data and safety monitoring board, the deferred-therapy group was modified, and infants in this group were all reassessed for initiation of antiretroviral therapy. CONCLUSIONS: Early HIV diagnosis and early antiretroviral therapy reduced early infant mortality by 76% and HIV progression by 75%. (ClinicalTrials.gov number, NCT00102960.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newell, M.-L., Coovadia, H., Cortina-Borja, M., Rollins, N., Gaillard, P., & Dabis, F. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17140-7 · Cited by 1,182
De, N., Rs, K., Rl, L., Chrismon, J. H., Merritt, R., Da, A., & Giovino, G. A. (1994) · PubMed · Cited by 797
PENTA guidelines for the use of antiretroviral therapy, 2004
Sharland, M., Blanche, S., Gattinara, G. C., Ramos, J. M., & Gibb, D. M. (2004) · HIV Medicine · doi:10.1111/j.1468-1293.2004.00227.x · Cited by 155
Self-citationA Trial of Three Antiretroviral Regimens in HIV-1–Infected Children
Luzuriaga, K., McManus, M. M., MOFENSON, L. M., Britto, P., Graham, B., & Sullivan, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032706 · Cited by 145
Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee (2008) · AIDS · doi:10.1097/01.aids.0000302262.51286.a5 · Cited by 142
&NA; (2002) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200203000-00012 · Cited by 119
Díaz, C., Hanson, C., Cooper, E. R., et al. (1998) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199807010-00004 · Cited by 67
Barthel, F. M.-S., Babiker, A. G., Royston, P. J., & Parmar, M. (2006) · Statistics in Medicine · doi:10.1002/sim.2517 · Cited by 65
Self-citation
Cited by
Point-of-care nucleic acid testing for infectious diseases
Niemz, A., Ferguson, T. M., & Boyle, D. S. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.01.007 · Cited by 838
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant
Persaud, D., Gay, H., Ziemniak, C., Chen, Y. H., Piatak, M., Chun, T.-W., Strain, M., Richman, D., & Luzuriaga, K. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302976 · Cited by 581
Perez-Velez, C. M., & Marais, B. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1008049 · Cited by 572
Bootstrap inference when using multiple imputation
Schomaker, M., & Heumann, C. (2018) · Statistics in Medicine · doi:10.1002/sim.7654 · Cited by 446
Marais, B. J., Lönnroth, K., Lawn, S. D., Migliori, G. B., Mwaba, P., Glaziou, P., Bates, M., Colagiuri, R., Zijenah, L., Swaminathan, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70015-x · Cited by 314
Neu, N., Duchon, J., & Zachariah, P. (2015) · Clinics in Perinatology · doi:10.1016/j.clp.2014.11.001 · Cited by 289
Brady, M. T., Oleske, J. M., Williams, P. L., Elgie, C., Mofenson, L. M., Dankner, W. M., & Van Dyke, R. B. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181b9869f · Cited by 278
A paper and plastic device for performing recombinase polymerase amplification of HIV DNA
Rohrman, B. A., & Richards-Kortum, R. R. (2012) · Lab on a Chip · doi:10.1039/c2lc40423k · Cited by 273
Universal Voluntary Testing and Treatment for Prevention of HIV Transmission
Dieffenbach, C. W. (2009) · JAMA · doi:10.1001/jama.2009.828 · Cited by 269
Boyle, D. S., Lehman, D. A., Lillis, L., Peterson, D., Singhal, M., Armes, N., Parker, M., Piepenburg, O., & Overbaugh, J. (2013) · mBio · doi:10.1128/mbio.00135-13 · Cited by 258
Braun, M., Kabue, M. M., McCollum, E. D., Ahmed, S., Kim, M., Aertker, L., Chirwa, M., Eliya, M., Mofolo, I., Hoffman, I., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31820a7f2f · Cited by 91
(2010) · PubMed · Cited by 52
Sutcliffe, C. G., Thuma, P. E., van Dijk, J. H., Sinywimaanzi, K., Mweetwa, S., Hamahuwa, M., & Moss, W. J. (2017) · BMC Pediatrics · doi:10.1186/s12887-017-0822-z · Cited by 41
Hartley, C., Pretorius, K., Mohamed, A., Laughton, B., Madhi, S., Cotton, M. F., Steyn, B., & Seedat, S. (2010) · Psychology, Health & Medicine · doi:10.1080/13548501003615258 · Cited by 43
Self-citationBhardwaj, S., Carter, B., Aarons, G. A., & Chi, B. H. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-015-0260-1 · Cited by 42
Computer-Generated Reminders and Quality of Pediatric HIV Care in a Resource-Limited Setting
Were, M. C., Nyandiko, W. M., Huang, K. T. L., Slaven, J. E., Shen, C., Tierney, W. M., & Vreeman, R. C. (2013) · Pediatrics · doi:10.1542/peds.2012-2072 · Cited by 28
Sacks, E., Cohn, J., Ochuka, B., Mafaune, H., Chadambuka, A., Odhiambo, C., Masaba, R., Githuka, G., Mahomva, A., Mushavi, A., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002383 · Cited by 20
Bonawitz, R., Sambambi, K., Vickery, M., Hamomba, L., Hammond, E., Duncan, J., Musokotwane, K., Thea, D., & Herlihy, J. M. (2016) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001155 · Cited by 5
Metadata
- Authors
- Violari, A., Cotton, M. F., Gibb, D. M., Babiker, A. G., Steyn, J., Madhi, S. A., Jean-Philippe, P., & McIntyre, J. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-11-20
- Volume
- 359
- Issue
- 21
- Pages
- 2233-2244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2122986037
- Cited by
- 1,418
- References
- 13
- FWCI
- 60.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.